ArriVent BioPharma, Inc.

SecurityAVBP / ArriVent BioPharma, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership128,546 shares
Latest Disclosed Value $ 2,965,556
Morgan Stanley reports 31.72% increase in ownership of AVBP / ArriVent BioPharma, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 128,546 shares of ArriVent BioPharma, Inc. (US:AVBP) valued at $2,965,556 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 97,590 shares of ArriVent BioPharma, Inc.. This represents a change in shares of 31.72% during the quarter. The current value of the position is $3,901,371 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARRIVENT BIOPHARMA COM 04272N102 128,546 30,956 31.72 2,966 51.04 0.0002
2026-05-27 2025-12-31 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 97,590 -294,432 -75.11 1,964 -72.86 0.0001
2026-02-13 2025-12-31 13F ARRIVENT BIOPHARMA COM 04272N102 97,590 -294,432 1,964 0.0001
2026-05-27 2025-09-30 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 392,022 290,668 286.78 7,233 227.83 0.0004
2025-11-14 2025-09-30 13F ARRIVENT BIOPHARMA COM 04272N102 392,022 290,668 7,233 0.0004
2025-08-15 2025-06-30 13F ARRIVENT BIOPHARMA COM 04272N102 101,354 -20,584 -16.88 2,206 -2.13 0.0001
2025-05-15 2025-03-31 13F ARRIVENT BIOPHARMA COM 04272N102 121,938 -26,646 -17.93 2,255 -43.05 0.0002
2025-05-15 2024-12-31 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 148,584 -19,150 -11.42 3,958 0.43 0.0003
2025-02-14 2024-12-31 13F ARRIVENT BIOPHARMA COM 04272N102 148,584 -19,150 3,958 0.0003
2025-05-14 2024-09-30 13F/A-2 ARRIVENT BIOPHARMA COM 04272N102 167,734 126,350 305.31 3,942 413.82 0.0003
2025-02-14 2024-09-30 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 167,734 126,350 3,942 0.0003
2024-11-14 2024-09-30 13F ARRIVENT BIOPHARMA COM 04272N102 167,734 126,350 3,942 0.0000
2025-05-14 2024-06-30 13F/A-2 ARRIVENT BIOPHARMA COM 04272N102 41,384 20,243 95.75 768 103.45 0.0001
2024-10-17 2024-06-30 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 41,384 20,243 768 0.0001
2024-08-14 2024-06-30 13F ARRIVENT BIOPHARMA COM 04272N102 41,384 20,243 768 0.0001
2024-10-17 2024-03-31 13F/A-2 ARRIVENT BIOPHARMA COM 04272N102 21,141 21,141 378 0.0000
2024-08-16 2024-03-31 13F/A-1 ARRIVENT BIOPHARMA COM 04272N102 21,141 21,141 378 0.0000
2024-05-15 2024-03-31 13F ARRIVENT BIOPHARMA COM 04272N102 21,141 21,141 378 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.